ClinicalTrials.gg
RecruitingNCT06614179Updated Sep 26, 2024

A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established

An observational study in Abdominal Neoplasm, sponsored by Xiangdong Cheng. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Xiangdong Cheng · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100,000
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Abdominal Neoplasms with a site in China — 5 open to participants now, 5 under way, 1 of them phase 3. Abdominal Neoplasms · China.

Started
2024
with 2 others
Observational
5 of 10
2 open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Xiangdong Cheng

Among the 10 studies in Abdominal Neoplasms with a site in China, this one is one of 3 that started in 2024, is one of 5 observational ones, and was the 7th registered.

Abdominal Neoplasms

42 studies on the registry are indexed under Abdominal Neoplasms; 14 are open to participants now.

Browse Abdominal Neoplasms studies →

Open to participants now

5 of the 10 studies in Abdominal Neoplasms with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 8 Abdominal Neoplasms studies recruiting now, 4 set no upper age limit and 4 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Abdominal Neoplasms with a site in China, or all of them as a file.
02

Study summary

Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors

Read the detailed description

Secondary objective: To establish a grading model of abdominal tumors based on clinical indicators Exploratory Objective: To include CT scans in large-scale non-tumor populations for validation and to improve model accuracy Certainty

03

Conditions studied

  • Abdominal Neoplasm

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with abdominal tumors or Non-tumor population

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with abdominal tumors:
  • all patients were diagnosed with abdominal tumors;
  • The clinical case data of all patients were complete, and complete follow-up was obtained, with clear information on medical visits, operation time and survival status within 2 years. If the cause of death is unknown, it will be recorded as censored data;
  • All patients had no history of active abdominal bleeding, no serious infection or other abdominal diseases that affected the observation of CT imaging within 3 months before surgery.
  • Non-tumor population:
  • all patients have complete clinical case data, complete abdominal CT, no history of malignant tumors, no serious infections or other abdominal diseases that affect the diagnosis and observation of CT imaging.

Exclusion criteria

Exclusion Criteria:

  • Cases in which contrast-enhanced or noncontrast CT images show unclear lesions, with significant noise and artifacts;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Whether or not there is a diagnosis of abdominal tumor questionnaire

    Whether or not there is a diagnosis of abdominal tumor

    Time frame: first visited at baseline

07

Study locations

2 of 2 sites recruiting
  • Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
    Hangzhou, Zhejiang 310000, China
    Recruiting
  • Zhejiang Cancer Hospital;Cancer hospital of the university of chinese academy of sciences
    Hangzhou, Zhejiang 310022, China
    Recruiting
    • Pengfei Yu, MD,PhD · Contactypfzmu@163.com · +86-571-88128031
    • Xiangdong Cheng, MD,PhD · Principal investigator
    • Yu Pengfei, MD,PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Dec 2029, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2024
First posted
Sep 26, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06614179
Lead sponsor
Xiangdong Cheng
Responsible party
Xiangdong Cheng (Professor, Zhejiang Cancer Hospital) — Sponsor-investigator
First posted
Sep 26, 2024
Start date
Jul 1, 2024
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 26, 2024

Study contacts

Xiangdong Cheng
Contact
Chengxd516@126.com
0086-571-881280
Can Hu
Contact
chengxd@zjcc.org.cn
13968032995
Xiangdong Cheng
principal investigator · Zhejiang Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion